Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.79 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770202 | 1.00 | PTGS2 (0.79) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL8770634 | 0.91 | PTGS2 (0.68) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL8646859 | 0.91 | PTGS2 (0.68) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL10300269 | 0.89 | PTGS2 (0.62) | PTGS2CA12CA2CA9PTGS1 | |
| SCHEMBL7677302 | 0.89 | PTGS2 (0.62) | PTGS2CA12CA2CA9PTGS1 | |
| SCHEMBL5502727 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL1676176 | 0.88 | PTGS2 (0.63) | PTGS2PTGS1 | |
| Hydrogen Sulfide SCHEMBL27744400 | 0.87 | PTGS2 (0.96) | PTGS2PTGS1 | |
| Cyclohexene SCHEMBL3252500 | 0.86 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL7566329 | 0.85 | PTGS2 (0.66) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377948-B2 | Antitumor agents and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-19 | — | — | US | claimed |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | US | claimed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | claimed |
| JP-2006516145-A | — | — | 2006-06-22 | — | — | JP | claimed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4393923-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | Yiyou Biotech (Shanghai) Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-117646044-A | Method for synthesizing (1R, 2R) -4-methylsulfonyl benzene silk amino alcohol by multi-enzyme cascade and application thereof | 福州大学 | 2024-03-05 | — | — | CN | disclosed |
| WO-2023115327-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-06-29 | — | — | WO | disclosed |
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
| EP-1037868-B1 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6437177-B1 | DISEASES INVOLVING CONNECTIVE TISSUE DEGRADATION; ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, DERMAL, OR GASTRIC ULCERATION, AND ASTHMA; 2-HYDROXY-2-(PHENYLTHIO) METHYL-3-(4-BUTOXYBENZENESULFONYL)PROPIONIC ACID | PHARMACIA & UPJOHN COMPANY | 2002-08-20 | — | — | US | disclosed |
| EP-1037868-A2 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999026909-A2 | ALPHA-HYDROXY, -AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0866367-A2 | Radiation sensitive composition | JSR Corporation (JP) | 1998-09-23 | — | — | EP | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | HSPA2, HSPBP1, HSP90AB1 | PTGS2 691/4885CA12 3645/4885CA1 1960/4885 |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | PTGS2 1526/4885CA12 1990/4885CA1 2760/4885 |
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | MCL1, TP53, MYC | PTGS2 4096/4885CA12 4416/4885CA1 4476/4885 |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | ADRB1, ADRA2A, ADRA1A | PTGS2 1229/4885CA12 3517/4885CA1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.